UHRF1蛋白在结直肠癌中的表达情况及其预后判断价值

doi:10.3969/j.issn.1004-616x.2015.01.007

癌变·畸变·突变

UHRF1蛋白在结直肠癌中的表达情况及其预后判断价值

吴李飞¹，郝佳洁²，张彤彤²，梁建伟³，王征³，张钰²，徐昕²，蔡岩²，王明荣^2，*，李敏^{1， *}

安徽医科大学附属安庆医院，安庆市立医院消化内科，安徽安庆 246003

收稿日期:2014-11-17 修回日期:2014-12-30 出版日期:2015-01-31 发布日期:2015-01-31
通讯作者: 王明荣，E-mail：wangmr2015@126.com；李敏，E-mail：lmin0556@163.com
作者简介:吴李飞，E-mail：wulifei0556@yeah.net
基金资助:
公益性行业科研专项(201402003)

Expression and prognostic value of UHRF1 in colorectal cancer

WU Lifei¹, HAO Jiajie²，ZHANG Tongtong²，LIANG Jianwei³，WANG Zheng³，ZHANG Yu²，XU Xin²，CAI Yan²，WANG Mingrong^2，*，LI Min^1，*

Department of Gastroenterology, Anqing City Hospital, Affiliated Anqing Hospital of Anhui Medical University, Anqing 246003, Anhui

Received:2014-11-17 Revised:2014-12-30 Online:2015-01-31 Published:2015-01-31

摘要/Abstract

摘要：

目的：探讨泛素样含PHD和环指域1(UHRF1)蛋白在结直肠癌中的表达及其预后判断价值。方法：采用组织微阵列联合免疫组织化学(TMA-IHC)技术检测201例结直肠癌中UHRF1蛋白的表达情况，分析其与临床病理指标及术后生存时间之间的相关性。结果：UHRF1蛋白在结直肠癌组织中的表达阳性率为54.2%(109/201)，显著高于配对的手术切端形态学正常的组织(P<0.01)。Kaplan-Meier生存分析显示，UHRF1蛋白表达阳性患者术后生存时间短于表达阴性的患者(P=0.023)。Cox回归分析结果表明，UHRF1蛋白是结直肠癌患者根治术后的一个独立预后因素(P=0.008)。结论：UHRF1蛋白可能作为结直肠癌患者术后预后判断的分子标志。

关键词: UHRF1, 结直肠癌, 分子标志, 预后判断

Abstract:

OBJECTIVE: This study aimed to evaluate the expression and prognostic significance of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) protein in colorectal cancer (CRC). METHODS：The expression of UHRF1 in 201 CRC cases and adjacent normal tissues were detected by tissue microarrays and immunohistochemistry (TMA-IHC)，then the relationship between UHRF1 protein expression and clinio-pathological parameters as well as its prognostic value were examined by statistical analysis. RESULTS：Positive expression of UHRF1 was observed in 54.2% (109/201) of CRC tissues，and the frequency in CRC was significantly higher than that in adjacent nomal tissues (P<0.01). Kaplan-Meier survival curves showed that CRC patients with negative expression of UHRF1 had shorter overall survival time (P=0.023). Cox regression analysis indicated that UHRF1 protein expression was an independent prognostic factor (P=0.008). CONCLUSION：UHRF1 might be a biomarker for prognostic evaluation of CRC patients.

Key words: UHRF1, colorectal cancer, molecular marker, prognostic evaluation

吴李飞，郝佳洁，张彤彤，梁建伟，王征，张钰，徐昕，蔡岩，王明荣，李敏. UHRF1蛋白在结直肠癌中的表达情况及其预后判断价值[J]. 癌变·畸变·突变, doi: 10.3969/j.issn.1004-616x.2015.01.007.

WU Lifei1, HAO Jiajie，ZHANG Tongtong，LIANG Jianwei，WANG Zheng，ZHANG Yu，XU Xin，CAI Yan，WANG Mingrong，LI Min. Expression and prognostic value of UHRF1 in colorectal cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, doi: 10.3969/j.issn.1004-616x.2015.01.007.

参考文献

[1] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer，2014. doi：10.1002/ijc. 29210.

[2] Bronner C，Achour M，Arima Y，et al. The UHRF family： oncogenes that are drugable targets for cancer therapy in the near future?[J]. Pharmacol Ther，2007，115(3)：419-434.

[3] Hopfner R，Mousli M，Jeltsch JM，et al. ICBP90，a novel human CCAAT binding protein，involved in the regulation of topoisomerase II alpha expression[J]. Cancer Res，2000， 60(1)：121-128.

[4] Daskalos A，Oleksiewicz U，Filia A，et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer[J]. Cancer，2011，117(5)：1027-1037.

[5] Unoki M，Daigo Y，Koinuma J，et al. UHRF1 is a novel diagnostic marker of lung cancer[J]. Br J Cancer，2010， 103(2)：217-222.

[6] Jin W，Chen L，Chen Y，et al. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer[J]. Breast Cancer Res Treat，2010，123(2)：359-373.

[7] Unoki M，Kelly JD，Neal DE，et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer[J]. Br J Cancer，2009，101(1)：98-105.

[8] Babbio F，Pistore C，Curti L，et al. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression[J]. Oncogene，2012，31(46)：4878-4887.

[9] Zhou L，Zhao X，Han Y，et al. Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis[J]. FASEB J，2013，27(12)：4929-4939.

[10] Pita JM，Banito A，Cavaco BM，et al. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas[J]. Br J Cancer，2009，101(10)：1782-1791.

[11] Pi JT，Lin Y，Quan Q，et al. Overexpression of UHRF1 is significantly associated with poor prognosis in laryngeal squamous cell carcinoma[J]. Med Oncol，2013，30(4)：613.

[12] Kofunato Y，Kumamoto K，Saitou K，et al. UHRF1 expression is upregulated and associated with cellular proliferation in colorectal cancer[J]. Oncol Rep，2012，28(6)： 1997-2002.

[13] Wang F，Yang YZ，Shi CZ，et al. UHRF1 promotes cell growth and metastasis through repression of p16ink(4)a in colorectal cancer[J]. Ann Surg Oncol，2012，19(8)：2753-2762.

[14] Jenkins Y，Markovtsov V，Lang W，et al. Critical role of the ubiquitin ligase activity of UHRF1，a nuclear RING finger protein，in tumor cell growth[J]. Mol Biol Cell，2005， 16(12)：5621-5629.

[15] Li X，Meng Q，Rosen EM，et al. UHRF1 confers radioresistance to human breast cancer cells[J]. Int J Radiat Biol，2011，87(3)：263-273.

[16] Abbady AQ，Bronner C，Trotzier MA，et al. ICBP90 expression is down-regulated in apoptosis-induced Jurkat cells[J]. Ann NY Acad Sci，2003，1010：300-303.

[17] Jeanblanc M，Mousli M，Hopfner R，et al. The retinoblastoma gene and its product are targeted by ICBP90：a key mechanism in the G1/S transition during the cell cycle[J]. Oncogene， 2005，24(49)：7337-7345.

[18] Un F，Qi C，Prosser M，et al. Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity[J]. Anticancer Res，2006，26 (4B)：2761-2767.

[19] Muto M，Kanari Y，Kubo E，et al. Targeted disruption of Np95 gene renders murine embryonic stem cells hypersensitive to DNA damaging agents and DNA replication blocks[J]. J Biol Chem，2002，277(37)：34549-34555.

[20] Hopfner R，Mousli M，Oudet P，et al. Overexpression of ICBP90，a novel CCAAT-binding protein，overcomes cell contact inhibition by forcing topoisomerase II alpha expression [J]. Anticancer Res，2002，22(6A)：3165-3170.

UHRF1蛋白在结直肠癌中的表达情况及其预后判断价值

Expression and prognostic value of UHRF1 in colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[2]	常晨, 杨荔艳, 蔡洪庆, 苑青, 郝佳洁, 王明荣. 食管鳞癌中SERPINE1 mRNA的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(4): 245-249.
[3]	李博, 李改瑞, 赵伟, 彭晓琳, 赵丹, 彭绩. 用于粪便DNA检测的样本保存液制作和效果评估[J]. 癌变·畸变·突变, 2021, 33(4): 312-316.
[4]	杨修远, 潘月龙. CD10蛋白在结直肠癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 344-349.
[5]	朱依青, 张彤彤, 郑珺文, 郝佳洁, 蔡岩, 王明荣, 梁建伟, 张钰. p-mTOR蛋白在结直肠癌组织中的表达及患者预后判断中的价值[J]. 癌变·畸变·突变, 2020, 32(3): 161-165.
[6]	陈秀琼, 孟凡桥, 熊华, 周洋媚, 唐雯华, 邹燕梅. 转移性结直肠癌抗EGFR治疗的耐药机制研究进展[J]. 癌变·畸变·突变, 2020, 32(1): 67-71.
[7]	马晓骉, 张麒, 潘定国. B7-H1基因rs4143815位点多态性与结直肠癌发病风险的关联研究[J]. 癌变·畸变·突变, 2019, 31(6): 440-443,448.
[8]	余明辰, 吴楠, 孙冬琳, 金焰. 胶质母细胞瘤分子标志物的研究进展[J]. 癌变·畸变·突变, 2019, 31(5): 412-416.
[9]	刘婷婷, 梁建伟, 余竟, 常晨, 郝佳洁, 蔡岩, 周志祥, 王明荣, 张彤彤, 张钰. 结直肠癌组织中KIAA1522的表达及临床意义[J]. 癌变·畸变·突变, 2017, 29(2): 87-90,95.
[10]	常晨, 赵霄瀚, 江烨, 徐昕, 蔡岩, 裴宇慧, 张钰, 郝佳洁, 王明荣. 食管鳞癌组织的常见基因组DNA异常改变及其临床预后的相关性分析[J]. 癌变·畸变·突变, 2017, 29(1): 1-6.
[11]	吴青松, 傅仲学. 中国人群中XRCC1 Arg194Trp位点多态性和结直肠癌易感性关系的Meta分析[J]. 癌变·畸变·突变, 2016, 28(2): 134-140.
[12]	任岩, 秦伟, 朱强强, 周丽华, 王婷. VEGF介导微囊藻毒素-LR促进结直肠癌细胞DLD-1侵袭迁移的研究[J]. 癌变·畸变·突变, 2015, 27(6): 441-445.
[13]	姚雨江, 谢妮, 刘丽桃, 李仲航, 万丽丽, 朱婷. 结直肠癌淋巴结转移相关基因标志物的筛选[J]. 癌变·畸变·突变, 2015, 27(5): 332-340,346.
[14]	史荣辉, 韩飞, 董严, 张明谦, 姜晓, 尹俐, 刘文斌, 曹佳, 刘晋祎. SOX30基因在结直肠癌中的表达与甲基化分析[J]. 癌变·畸变·突变, 2015, 27(3): 168-171,176.
[15]	李夏君，杨淼，董自成，刘冉，尹立红，浦跃朴. LncRNA-UCA1与淮安食管癌发病风险的初步研究[J]. 癌变·畸变·突变, 2014, 26(6): 407-411.